Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688711 | 1.00 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8606527 | 0.88 | LMNA (0.66) | LMNASMN1; SMN2MEN1KMT2AMAOB | |
| SCHEMBL4052228 | 0.86 | LMNA (0.72) | LMNACYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL10492673 | 0.85 | RAB9A (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL10474044 | 0.85 | LMNA (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3254859 | 0.85 | LMNA (1.00) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL50453 | 0.85 | LMNA (1.00) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2943775 | 0.85 | LMNA (1.00) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1618880 | 0.85 | LMNA (1.00) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9637755 | 0.84 | MAOB (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-0280419-B1 | OPTICALLY ACTIVE-2-SUBSTITUTED-PROPYL ETHER AND LIQUID CRYSTAL COMPOSITION | Chisso Corporation (JP) | 1992-07-08 | — | — | EP | disclosed |
| US-5032314-A | Optically active 2-substituted-propyl ether and a liquid crystal composition | CHISSO CORPORATION (JP) | 1991-07-16 | — | — | US | disclosed |
| EP-0280419-A2 | Optically active-2-substituted-propyl ether and liquid crystal composition | Chisso Corporation (JP) | 1988-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | LMNA 4294/4885CYP1A2 3726/4885PTGS1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.